Volume Alert - BMY 58.16 Bristol-Myers Squibb Company $BMY Hit a high today of 58.32 Closing the day 10:30 at 58.16 -0.45 -0.77% With a day low of 57.92 and a total volume of 1,908,486.
BMY Recent Posts: http://investorshangout.com/Bristol-Myers-Squ...BMY-50337/
BMY Bristol-Myers Squibb Company Recent Headline News
Early Glance: Pharmaceuticals companies
AP - 18 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.92 (+0.17), BAX: 72.10 (+0.77), PFE: 30.50 (+0.08), BMY: 57.93 (-0.68)
Ad Comm meeting approaches to discuss risks of epidural steroid injections
Seeking Alpha - at Seeking Alpha - 37 mins ago
PFE: 30.50 (+0.08), MRK: 59.69 (+0.38), BMY: 57.93 (-0.68), NVS: 94.47 (+1.81)
Bristol-Myers Squibb (BMY) Approaches New Downside Target of $58.05
Comtex SmarTrend(R) - 1 hr 53 mins ago
Shares of Bristol-Myers Squibb (NYSE:BMY) opened today below their pivot of $58.56 and have already reached the first level of support at $58.33. Investors may be interested in a cross of the next downside pivot targets of $58.05 and $57.54.
BMY: 57.93 (-0.68)
Must-See Charts: How to Trade SPY, DaVita, GM, Bristol-Myers Squibb, National Grid
at The Street - 2 hrs 42 mins ago
Skilled technical traders can bank gains as much as 90% of the time.
SPY: 204.17 (+0.21), DVA: 76.82 (+0.10), GM: 31.71 (+0.29), BMY: 57.93 (-0.68), NGG: 74.15 (-0.14)
Global Immune Checkpoint Inhibitors Market, 2014-2024: Yervoy, Opdivo and Keytruda to Achieve Blockbuster Status in the Near Future
M2 - Thu Nov 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkbg4v/immune_checkpoint) has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering. The Immune Checkpoint Inhibitors Market, 2014-2024 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. Key Highlights - The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules. - BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Immuno-Oncology 4. Current Market Landscape 5. CTLA-4 Inhibitors: Key Molecules and Future Outlook 6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook 7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook 8. Competition in Key Indication Areas 9. Deals and Partnerships 10. Company Profiles 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Bristol Myer Squibb - AstraZeneca - Merck & Co. - Roche / Genentech - Incyte Corporation - NewLink Genetics - arGEN-X - Seattle Genetics - Pfizer - MacroGenics - Celldex Therapeutics - CureTech - Immutep - Innate Pharma - Sorrento Therapeutics - GlaxoSmithKline - GITR, Inc. For more information visit http://www.researchandmarkets.com/research/fk...checkpoint
MRK: 59.69 (+0.38), INCY: 71.61 (-0.26), CLDX: 14.58 (-0.23), NLNK: 31.47 (-0.92), GSK: 45.66 (+0.04), BMY: 57.93 (-0.68), SRNE: 4.29 (-0.15)
New study involving 10 canadian research sites shows high cure rates for genotype 1 hepatitis C using new Bristol-Myers Squibb all-oral daclatasvir TRIO fixed-dose combination
CNW Group - Thu Nov 13, 4:59AM CST
Ten Canadian research sites were among those that participated in a study whose results announced this week show high cure rates for patients with genotype 1 hepatitis C, including those with cirrhosis, after a 12-week regimen of the new Bristol-Myers Squibb all-oral daclatasvir (DCV) TRIO regimen - a fixed-dose combination of daclatasvir with asunaprevir (ASV) and beclabuvir (BCV) treatment
BMY: 57.93 (-0.68)
Bristol-Myers Squibb announces high cure rates for genotype 3 hepatitis C using combination of daclatasvir and sofosbuvir in ALLY-3 trial
CNW Group - Thu Nov 13, 4:59AM CST
Results of the landmark ALLY-3 trial announced this week show sustained virologic response after 12 weeks of treatment (SVR12) in 90% of treatment-naïve and 86% of treatment-experienced patients with genotype 3 hepatitis C (HCV) who received the investigational Bristol-Myers Squibb treatment daclatasvir in combination with sofosbuvir.
BMY: 57.93 (-0.68)
Acute Coronary Syndrome: Global Drug Forecast and Market Analysis to 2023 - Market to Triple from $12.3 Billion in 2013 to $43.4 Billion by 2023
M2 - Thu Nov 13, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/mhkp4w/pharmapoint) has announced the addition of the "PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023" report to their offering. New Blockbuster Drugs to More than Triple Acute Coronary Syndrome Treatment Market Value by 2023 The launch of several drugs with extraordinary blockbuster potential will cause the acute coronary syndrome (ACS) treatment market to more than triple in value, from $12.3 billion in 2013 to $43.4 billion by 2023 This report states that across seven major markets (the US, France, Germany, Italy, Spain, the UK and Japan) there are three monoclonal antibodies (mAbs), all PCSK9 inhibitors, with the potential to reshape the post-ACS, dyslipidemia landscape. Amgen's evolocumab, Sanofi and Regeneron's alirocumab, and Pfizer's bococizumab are all demonstrating safe and significant reductions of serum LDL-C levels in major clinical trials, and The authors expects these treatments to be launched in the middle of the forecast period. Eric J. Dimise, Ph.D., The authors's Analyst covering Cardiovascular and Metabolic Disorders, says: These three mAbs, which fulfill a critical unmet need by offering novel approaches to LDL-C reduction for patients who cannot tolerate statins, are likely to be prescribed long-term, marking the first time that biologics will enter the mainstream of chronic ACS treatment. The premium price of PCSK9 mAbs means that they will be able to achieve substantial sales with a relatively small patient population. We forecast that they will account for around 40% of ACS sales by 2023, with a global value that slightly exceeds $17.5 billion. The authors has also identified two new anticoagulants, Janssen's Xarelto and Merck's Zontivity, which are both on track to compete directly with warfarin and post impressive sales over the next nine years. Dimise states: Xarelto is anticipated to achieve approval for the ACS indication in the US by 2018. When added to the drug's mounting sales in the EU, this will result in peak-year sales approaching $8 billion for ACS alone. Meanwhile, the PAR1 inhibitor, Zontivity, which enters the US market in Q3 of 2014, could achieve worldwide sales exceeding $1 billion by 2015. The dramatic increase in overall ACS market value is attributable to the launch of these and several other drugs currently in the late-stage development pipeline, all of which have extraordinary blockbuster potential, concludes the analyst. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Unmet Need and Opportunity 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Amgen - AstraZeneca - Bristol-Myers Squibb - Daiichi Sankyo - Eli Lilly - GlaxoSmithKline - Janssen Pharmaceuticals (Johnson & Johnson) - The Medicines Company - Merck & Co. - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/mh...harmapoint
JNJ: 108.92 (+0.17), MRK: 59.69 (+0.38), AMGN: 160.58 (-1.35), LLY: 67.88 (+0.48), GSK: 45.66 (+0.04), BMY: 57.93 (-0.68)
Final Glance: Pharmaceuticals companies
AP - Wed Nov 12, 5:02PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.92 (+0.17), BAX: 72.10 (+0.77), PFE: 30.50 (+0.08), BMY: 57.93 (-0.68)
Midday Glance: Pharmaceuticals companies
AP - Wed Nov 12, 12:23PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.92 (+0.17), BAX: 72.10 (+0.77), PFE: 30.50 (+0.08), BMY: 57.93 (-0.68)
Bristol-Myers Squibb to Present Sixteen Orencia (abatacept) Data Abstracts at The American College of Rheumatology (ACR) 2014 Annual Meeting
Business Wire - Wed Nov 12, 7:36AM CST
--Real-world data highlighting meaningful patient-reported outcomes and reinforcing the established safety data of Orencia
BMY: 57.93 (-0.68)
Food Allergy Global Clinical Trials Review, H2, 2014
M2 - Wed Nov 12, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/cjd7jz/food_allergy) has announced the addition of the "Food Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Food Allergy Global Clinical Trials Review, H2, 2014" provides data on the Food Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Food Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Food Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Food Allergy Therapeutics Clinical Trials - United Pharmaceuticals SA - DBV Technologies SA - Mead Johnson Nutrition Company - Danone Research B.V. - Friesland Coberco Dairy Foods Holding N.V. - Danone SA - Cosmetique Active International S.N.C. - Bristol-Myers Squibb Company - Allertein Therapeutics, LLC Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Federico II University - Mount Sinai Hospital - Nambudripad's Allergy Research Foundation - Stanford University - Helsinki University Central Hospital - National Center for Child Health and Development - Osaka Prefectural Medical Center for Respiratory and Allergic Diseases - The University of North Carolina at Chapel Hill - Murdoch Childrens Research Institute For more information visit http://www.researchandmarkets.com/research/cj...od_allergy
MJN: 98.82 (-0.79), DBVT: 24.95 (+1.42), BMY: 57.93 (-0.68)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 196.57 (+0.06), GILD: 104.92 (-1.98), ABBV: 63.92 (+0.16), BMY: 57.93 (-0.68)
Bristol-Myers Squibb's (BMY) CFO Charlie Banccroft on Credit Suisse Healthcare Conference - Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 4:43PM CST
BMY: 57.93 (-0.68)
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 104.92 (-1.98), ACHN: 13.91 (-0.94), MRK: 59.69 (+0.38), ABBV: 63.92 (+0.16), BMY: 57.93 (-0.68)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 108.92 (+0.17), GILD: 104.93 (-1.97), ACHN: 13.91 (-0.94), CNAT: 7.22 (+0.32), MRK: 59.69 (+0.38), RGLS: 18.26 (-1.36), ABBV: 63.92 (+0.16), BMY: 57.93 (-0.68), ENTA: 43.79 (+0.48)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 113.79 (-2.89), GILD: 104.93 (-1.97), MRK: 59.69 (+0.38), DNDN: 0.14 (-0.02), AZN: 74.67 (+0.41), TEVA: 57.71 (-0.73), ABBV: 63.92 (+0.16), GSK: 45.66 (+0.04), BMY: 57.93 (-0.68), NVS: 94.47 (+1.81)
BMY Recent Posts: http://investorshangout.com/Bristol-Myers-Squ...BMY-50337/
BMY Bristol-Myers Squibb Company Recent Headline News
Early Glance: Pharmaceuticals companies
AP - 18 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.92 (+0.17), BAX: 72.10 (+0.77), PFE: 30.50 (+0.08), BMY: 57.93 (-0.68)
Ad Comm meeting approaches to discuss risks of epidural steroid injections
Seeking Alpha - at Seeking Alpha - 37 mins ago
PFE: 30.50 (+0.08), MRK: 59.69 (+0.38), BMY: 57.93 (-0.68), NVS: 94.47 (+1.81)
Bristol-Myers Squibb (BMY) Approaches New Downside Target of $58.05
Comtex SmarTrend(R) - 1 hr 53 mins ago
Shares of Bristol-Myers Squibb (NYSE:BMY) opened today below their pivot of $58.56 and have already reached the first level of support at $58.33. Investors may be interested in a cross of the next downside pivot targets of $58.05 and $57.54.
BMY: 57.93 (-0.68)
Must-See Charts: How to Trade SPY, DaVita, GM, Bristol-Myers Squibb, National Grid
at The Street - 2 hrs 42 mins ago
Skilled technical traders can bank gains as much as 90% of the time.
SPY: 204.17 (+0.21), DVA: 76.82 (+0.10), GM: 31.71 (+0.29), BMY: 57.93 (-0.68), NGG: 74.15 (-0.14)
Global Immune Checkpoint Inhibitors Market, 2014-2024: Yervoy, Opdivo and Keytruda to Achieve Blockbuster Status in the Near Future
M2 - Thu Nov 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkbg4v/immune_checkpoint) has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering. The Immune Checkpoint Inhibitors Market, 2014-2024 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. Key Highlights - The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules. - BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Immuno-Oncology 4. Current Market Landscape 5. CTLA-4 Inhibitors: Key Molecules and Future Outlook 6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook 7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook 8. Competition in Key Indication Areas 9. Deals and Partnerships 10. Company Profiles 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Bristol Myer Squibb - AstraZeneca - Merck & Co. - Roche / Genentech - Incyte Corporation - NewLink Genetics - arGEN-X - Seattle Genetics - Pfizer - MacroGenics - Celldex Therapeutics - CureTech - Immutep - Innate Pharma - Sorrento Therapeutics - GlaxoSmithKline - GITR, Inc. For more information visit http://www.researchandmarkets.com/research/fk...checkpoint
MRK: 59.69 (+0.38), INCY: 71.61 (-0.26), CLDX: 14.58 (-0.23), NLNK: 31.47 (-0.92), GSK: 45.66 (+0.04), BMY: 57.93 (-0.68), SRNE: 4.29 (-0.15)
New study involving 10 canadian research sites shows high cure rates for genotype 1 hepatitis C using new Bristol-Myers Squibb all-oral daclatasvir TRIO fixed-dose combination
CNW Group - Thu Nov 13, 4:59AM CST
Ten Canadian research sites were among those that participated in a study whose results announced this week show high cure rates for patients with genotype 1 hepatitis C, including those with cirrhosis, after a 12-week regimen of the new Bristol-Myers Squibb all-oral daclatasvir (DCV) TRIO regimen - a fixed-dose combination of daclatasvir with asunaprevir (ASV) and beclabuvir (BCV) treatment
BMY: 57.93 (-0.68)
Bristol-Myers Squibb announces high cure rates for genotype 3 hepatitis C using combination of daclatasvir and sofosbuvir in ALLY-3 trial
CNW Group - Thu Nov 13, 4:59AM CST
Results of the landmark ALLY-3 trial announced this week show sustained virologic response after 12 weeks of treatment (SVR12) in 90% of treatment-naïve and 86% of treatment-experienced patients with genotype 3 hepatitis C (HCV) who received the investigational Bristol-Myers Squibb treatment daclatasvir in combination with sofosbuvir.
BMY: 57.93 (-0.68)
Acute Coronary Syndrome: Global Drug Forecast and Market Analysis to 2023 - Market to Triple from $12.3 Billion in 2013 to $43.4 Billion by 2023
M2 - Thu Nov 13, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/mhkp4w/pharmapoint) has announced the addition of the "PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023" report to their offering. New Blockbuster Drugs to More than Triple Acute Coronary Syndrome Treatment Market Value by 2023 The launch of several drugs with extraordinary blockbuster potential will cause the acute coronary syndrome (ACS) treatment market to more than triple in value, from $12.3 billion in 2013 to $43.4 billion by 2023 This report states that across seven major markets (the US, France, Germany, Italy, Spain, the UK and Japan) there are three monoclonal antibodies (mAbs), all PCSK9 inhibitors, with the potential to reshape the post-ACS, dyslipidemia landscape. Amgen's evolocumab, Sanofi and Regeneron's alirocumab, and Pfizer's bococizumab are all demonstrating safe and significant reductions of serum LDL-C levels in major clinical trials, and The authors expects these treatments to be launched in the middle of the forecast period. Eric J. Dimise, Ph.D., The authors's Analyst covering Cardiovascular and Metabolic Disorders, says: These three mAbs, which fulfill a critical unmet need by offering novel approaches to LDL-C reduction for patients who cannot tolerate statins, are likely to be prescribed long-term, marking the first time that biologics will enter the mainstream of chronic ACS treatment. The premium price of PCSK9 mAbs means that they will be able to achieve substantial sales with a relatively small patient population. We forecast that they will account for around 40% of ACS sales by 2023, with a global value that slightly exceeds $17.5 billion. The authors has also identified two new anticoagulants, Janssen's Xarelto and Merck's Zontivity, which are both on track to compete directly with warfarin and post impressive sales over the next nine years. Dimise states: Xarelto is anticipated to achieve approval for the ACS indication in the US by 2018. When added to the drug's mounting sales in the EU, this will result in peak-year sales approaching $8 billion for ACS alone. Meanwhile, the PAR1 inhibitor, Zontivity, which enters the US market in Q3 of 2014, could achieve worldwide sales exceeding $1 billion by 2015. The dramatic increase in overall ACS market value is attributable to the launch of these and several other drugs currently in the late-stage development pipeline, all of which have extraordinary blockbuster potential, concludes the analyst. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Unmet Need and Opportunity 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Amgen - AstraZeneca - Bristol-Myers Squibb - Daiichi Sankyo - Eli Lilly - GlaxoSmithKline - Janssen Pharmaceuticals (Johnson & Johnson) - The Medicines Company - Merck & Co. - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/mh...harmapoint
JNJ: 108.92 (+0.17), MRK: 59.69 (+0.38), AMGN: 160.58 (-1.35), LLY: 67.88 (+0.48), GSK: 45.66 (+0.04), BMY: 57.93 (-0.68)
Final Glance: Pharmaceuticals companies
AP - Wed Nov 12, 5:02PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.92 (+0.17), BAX: 72.10 (+0.77), PFE: 30.50 (+0.08), BMY: 57.93 (-0.68)
Midday Glance: Pharmaceuticals companies
AP - Wed Nov 12, 12:23PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.92 (+0.17), BAX: 72.10 (+0.77), PFE: 30.50 (+0.08), BMY: 57.93 (-0.68)
Bristol-Myers Squibb to Present Sixteen Orencia (abatacept) Data Abstracts at The American College of Rheumatology (ACR) 2014 Annual Meeting
Business Wire - Wed Nov 12, 7:36AM CST
--Real-world data highlighting meaningful patient-reported outcomes and reinforcing the established safety data of Orencia
BMY: 57.93 (-0.68)
Food Allergy Global Clinical Trials Review, H2, 2014
M2 - Wed Nov 12, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/cjd7jz/food_allergy) has announced the addition of the "Food Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Food Allergy Global Clinical Trials Review, H2, 2014" provides data on the Food Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Food Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Food Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Food Allergy Therapeutics Clinical Trials - United Pharmaceuticals SA - DBV Technologies SA - Mead Johnson Nutrition Company - Danone Research B.V. - Friesland Coberco Dairy Foods Holding N.V. - Danone SA - Cosmetique Active International S.N.C. - Bristol-Myers Squibb Company - Allertein Therapeutics, LLC Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Federico II University - Mount Sinai Hospital - Nambudripad's Allergy Research Foundation - Stanford University - Helsinki University Central Hospital - National Center for Child Health and Development - Osaka Prefectural Medical Center for Respiratory and Allergic Diseases - The University of North Carolina at Chapel Hill - Murdoch Childrens Research Institute For more information visit http://www.researchandmarkets.com/research/cj...od_allergy
MJN: 98.82 (-0.79), DBVT: 24.95 (+1.42), BMY: 57.93 (-0.68)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 196.57 (+0.06), GILD: 104.92 (-1.98), ABBV: 63.92 (+0.16), BMY: 57.93 (-0.68)
Bristol-Myers Squibb's (BMY) CFO Charlie Banccroft on Credit Suisse Healthcare Conference - Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 4:43PM CST
BMY: 57.93 (-0.68)
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 104.92 (-1.98), ACHN: 13.91 (-0.94), MRK: 59.69 (+0.38), ABBV: 63.92 (+0.16), BMY: 57.93 (-0.68)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 108.92 (+0.17), GILD: 104.93 (-1.97), ACHN: 13.91 (-0.94), CNAT: 7.22 (+0.32), MRK: 59.69 (+0.38), RGLS: 18.26 (-1.36), ABBV: 63.92 (+0.16), BMY: 57.93 (-0.68), ENTA: 43.79 (+0.48)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 113.79 (-2.89), GILD: 104.93 (-1.97), MRK: 59.69 (+0.38), DNDN: 0.14 (-0.02), AZN: 74.67 (+0.41), TEVA: 57.71 (-0.73), ABBV: 63.92 (+0.16), GSK: 45.66 (+0.04), BMY: 57.93 (-0.68), NVS: 94.47 (+1.81)
